• RI - Unifesp
    • Documentos
    • Tutoriais
    • Perguntas frequentes
    • Atendimento
    • Equipe
    • português (Brasil)
    • English
    • español
  • Sobre
    • RI Unifesp
    • Documentos
    • Tutoriais
    • Perguntas frequentes
    • Atendimento
    • Equipe
  • português (Brasil) 
    • português (Brasil)
    • English
    • español
    • português (Brasil)
    • English
    • español
  • Entrar
Ver item 
  •   Página inicial
  • Escola Paulista de Medicina (EPM)
  • EPM - Artigos
  • Ver item
  •   Página inicial
  • Escola Paulista de Medicina (EPM)
  • EPM - Artigos
  • Ver item
JavaScript is disabled for your browser. Some features of this site may not work without it.

Use of Topical Cannabinomimetic Palmitoylethanolamide in Ocular Surface Disease Associated with Antiglaucoma Medications

Thumbnail
Data
2017
Autor(a)
Di Zazzo, Antonio
Roberti, Gloria
Mashaghi, Alireza
Abud, Tulio Batista [UNIFESP]
Pavese, Daniela
Bonini, Stefano
Tipo
Artigo
ISSN
1080-7683
É parte de
Journal Of Ocular Pharmacology And Therapeutics
DOI
10.1089/jop.2016.0117
Metadado
Mostrar registro completo
Resumo
Purpose: Chronic use of topical hypotensive therapies in glaucoma patients leads to chronic inflammation of the ocular surface, which decreases the success rate of long-term glaucoma management. The aim of this study is to evaluate the effect of topical palmitoylethanolamide (PEA) (Defluxa((c))), a well-known anti-inflammatory and analgesic agent, in suppressing the ocular surface inflammation associated with the use of hypotensive eye drops. Methods: In a pilot clinical trial, we enrolled 15 glaucomatous patients who received topical PEA (Defluxa) in addition to the current antiglaucoma drugs, while 15 glaucomatous patients did not receive any additional treatment. At 3 different time points (day 0, 15, and 30), signs of ocular surface involvement, adverse events, visual acuity, and intraocular pressure were assessed. Results: Topical PEA (Defluxa) was effective in increasing the Schirmer test (P<0.05) and the tear film breakup time (T-BUT) (P<0.0001), and improving the conjunctival hyperemia (P<0.0001) by day 30, compared to baseline. Compared to control, by day 15, the conjunctival hyperemia score was significantly decreased in the PEA (Defluxa) group (P<0.01), while the T-BUT and the Schirmer Test achieved a significant improvement by day 30 (P<0.05; P<0.01). Discussion: Our data suggests that topical PEA (Defluxa) is a safe, effective, and generally well-tolerated treatment to prevent or suppress ocular surface inflammation attributable to chronic glaucoma treatment.
Citação
Journal Of Ocular Pharmacology And Therapeutics. New Rochelle, v. 33, n. 9, p. 670-677, 2017.
Palavras-chave
palmitoylethanolamide
dry eye
glaucoma
inflammation
ocular surface
antiglaucoma drugs
Agência(s) de Fomento
Ministry of Health
Fondazione Roma
URI
https://repositorio.unifesp.br/handle/11600/58302
Coleções
  • EPM - Artigos [16058]

DSpace software copyright © 2002-2016  DuraSpace
Entre em contato
Theme by 
Atmire NV
 

 

Navegar

Todo o repositórioComunidades e ColeçõesPor data do documentoAutoresTítulosAssuntosPor data de submissãoEsta coleçãoPor data do documentoAutoresTítulosAssuntosPor data de submissão

Minha conta

Entrar

Estatística

Ver as estatísticas de uso

DSpace software copyright © 2002-2016  DuraSpace
Entre em contato
Theme by 
Atmire NV